Free Trial
NASDAQ:ABVC

ABVC BioPharma Q1 2026 Earnings Results & Report

ABVC BioPharma logo
$0.94 +0.03 (+3.30%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ABVC BioPharma reported Q1 2026 earnings on May 18, 2026. The company reported EPS of -$0.06.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

ABVC BioPharma EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

ABVC BioPharma Q1 2026 Earnings FAQ

ABVC BioPharma (NASDAQ:ABVC) reported earnings of -$0.06 per share for Q1 2026. The report was announced on Monday, May 18, 2026.

ABVC BioPharma Earnings Headlines

/C O R R E C T I O N - WallachBeth Capital LLC/
A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
ABVC BioPharma Delays Quarterly SEC Filing
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company focused on developing botanical drug candidates and medical devices. The company conducts research and development through its subsidiaries and external partners.

Its pipeline includes ABV-1504, a botanical drug candidate being developed for major depressive disorder, and ABV-1505, a candidate for attention-deficit/hyperactivity disorder. These products remain in development and are not described as approved treatments.

Founded in 2015 and headquartered in Fremont, California, ABVC also pursues development opportunities in oncology and other therapeutic areas. Its work includes collaborations and licensing arrangements to advance its product candidates.

View ABVC BioPharma Profile